
BiotechTV - News Pareto Securities' Healthcare Conference: Guard Therapeutics will have a key P2b trial read for its kidney protecting therapy RCM-035 in the 4th quarter - CEO Tobias Agervald walks us through it
Sep 16, 2025
Chapters
Transcript
Episode notes
